In EGFR-mutant NSCLC that is resistant to the tyrosine kinase inhibitor gefitinib, activation of STAT3 caused the upregulation of PD-L1 expression while its inhibition led to the downregulation of PD-L1. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.